Fig. 1 · Structure

Documents & Downloads

Amuvatinib (MP470)

Cat. No. A10610 CAS 850879-09-3

RTK inhibitor

MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
c-Kit (D816H) 10 nM
PDGFRα (V561D) 40 nM
FLT3 (D835Y) 81 nM

Cellular Effect

Cell Line Activity Value Description Reference
Caco-2 IC50 0.02 μM Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging 10.21203/rs.3.rs-23951/v1
Caco-2 CC50 0.06 μM Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay 10.21203/rs.3.rs-23951/v1

Amuvatinib (MP470) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Amuvatinib (MP470) from 3 published references. In vitro models include Vero E6 cells; U266 cells.

Amuvatinib (MP470) In Vitro Studies

Amuvatinib blocked SARS-CoV-2 infection in Vero E6 cells, with an EC50 of 0.36 μM determined by qRT-PCR. In U266 cells, Amuvatinib at 5 μM produced ~40% growth inhibition after 48 and 72 h of incubation. In LNCaP cells exposed to varying concentrations of Amuvatinib for 4 days, MTS analysis yielded an IC50 of ~4 μM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Amuvatinib Inhibition of Viral Infection in Vero Cells

Cell-based study · Vero E6 cells [1]

Vero E6 cells were exposed to various concentrations of Amuvatinib. Amuvatinib blocked SARS-CoV-2 infection, with an EC50 of 0.36 μM determined by qRT-PCR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the EC50 value was determined by qRT-PCREC50 0.36 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
for 1 h; further cultured in fresh media containing amuvatinib; At 24 h postinfection
Method
in the absence or presence of various concentrations of amuvatinib
Co-treatment
Other interventions in this design: SARS-CoV-2 MOI = 0.01. Compound effect isolated by the comparison: in the absence or presence of various concentrations of amuvatinib.
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Amuvatinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Characterization of amuvatinib as an anti-SARS-CoV-2 agent. (S22); FIG 2 legend (S142, S143, S146, S147)

the EC50 value was determined by qRT-PCR: the EC50 value was determined by qRT-PCR; comparator: in the absence or presence of various concentrations of amuvatinib — RESULTS > Characterization of amuvatinib as an anti-SARS-CoV-2 agent. (S22); FIG 2 legend (S147)

Amuvatinib Growth Inhibition in Myeloma Cells

Cell-based study · U266 cells [2]

U266 cells were treated with Amuvatinib at 5 μM. Growth inhibition was ~40% after 48 and 72 h of incubation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell growth inhibitiongrowth ~40%[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
48 and 72 h of incubation
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Amuvatinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effect of Amuvatinib on Growth Inhibition (S28, S29); Methods > Materials (S89); Methods > Cell culture and growth analysis (S102)

cell growth inhibition: cell growth inhibition; comparator: DMSO-treated control cells — Results > Effect of Amuvatinib on Growth Inhibition (S29); Methods > Cell culture and growth analysis (S102)

Amuvatinib Effects on LNCaP Cell Viability

Cell-based study · LNCaP [3]

LNCaP cells were exposed to varying concentrations of Amuvatinib for 4 days. Cell viability assessed by MTS analysis yielded an IC50 of ~4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was assessed by MTS analysis.IC50 ~4 μM[3]

Literature-Reported Treatment Conditions

Treatment concentration
varying concentrations
Exposure duration
for 4 days
Method
exposed to varying concentrations of MP470
Vehicle
DMSO
Reported limits
Not stated in the sentences used: control.
Methods and source locations

Compound reported in the paper: Amuvatinib; Compound label in the paper: MP470

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cells and reagents (S7); Results > MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis (S77); Figure 1 legend (S131, S132, S134)

Cell viability was assessed by MTS analysis.: Cell viability was assessed by MTS analysis. — Results > MP470 alone or in combination with Erlotinib inhibits prostate cancer cell proliferation, promotes cell cycle arrest and apoptosis (S77); Figure 1 legend (S132, S134)

Amuvatinib (MP470) In Vivo Studies

SCID male mice bearing LNCaP xenografts received Amuvatinib IP at 50 mg/kg daily for 14 days. Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition. [3]

Amuvatinib Treatment in LNCaP Xenografts

Animal study · SCID male mice; LNCaP xenograft; 12 mice/group [3]

SCID male mice bearing LNCaP xenografts received Amuvatinib IP at 50 mg/kg daily for 14 days. Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
mean tumor volume ± SEMReported result Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI)[3]

Conditions shared by the study groups

Route
IP
Treatment course
daily for 14 days (starting day 30 and ending day 44)
Vehicle
5% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Amuvatinib 50 mg/kgDMSO (control)Individual therapy with MP470 or Erlotinib showed modest tumor growth inhibition (TGI)[3]
Amuvatinib 50 mg/kg
Model: SCID male mice; LNCaP xenograft; 12 mice/group
Methods and source locations

Compound reported in the paper: Amuvatinib; Compound label in the paper: MP470

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animal experiments (S53); Results > MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice (S120, S121); Figure 7 legend (S180, S182, S183, S184)

mean tumor volume ± SEM: mean tumor volume ± SEM; comparator: DMSO (control) — Results > MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice (S121); Figure 7 legend (S184)

Amuvatinib 50 mg/kg · Results > MP470 plus Erlotinib inhibits prostate cancer tumor growth in xenograft mice (S121); Figure 7 legend (S184)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 850879-09-3
Applications RTK inhibitor
Formula C23H21N5O3S
Molecular Weight 447.5
Synonyms MP470
SMILES
C1CN(CCN1C2=NC=NC3=C2OC4=CC=CC=C43)C(=S)NCC5=CC6=C(C=C5)OCO6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (67.03 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4.2 mg/mL
Vehicle
5%DMSO+95% Corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Amuvatinib (MP470) Research References

  1. [1] Huynh TTX, Pham TX, Lee GH, et al. Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle. Microbiol Spectr (2023). PMID: 36995225 DOI: 10.1128/spectrum.05105-22 Source material
  2. [2] Phillip CJ, Zaman S, Shentu S, et al. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol (2013). PMID: 24326130 DOI: 10.1186/1756-8722-6-92 Source material
  3. [3] Qi W, Cooke LS, Stejskal A, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer (2009). PMID: 19432987 DOI: 10.1186/1471-2407-9-142 Source material

Added to your cart

View Cart Checkout
Loading...